Treatment News : Pre-Exposure Prophylaxis is Cost-Effective in Some Settings

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » March 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

March 28, 2013

Pre-Exposure Prophylaxis is Cost-Effective in Some Settings

Pre-exposure prophylaxis (PrEP), which is when people at high risk of HIV take antiretrovirals (ARVs) as a means of lowering that risk, is cost-effective in some settings.  Researchers from various countries conducted an analysis of 13 modeling studies, evaluating PrEP’s impact in various populations—including heterosexual couples, men who have sex with men (MSM), and injection drug users—and in different areas and countries, such as southern Africa, Ukraine, the United States and Peru. They published their findings in the journal PLOS Medicine.

The investigators found that giving PrEP to higher risk groups appeared to be the most cost-effective prevention strategy. They also found that behavioral change—such as change in number of sexual partners—as well as adherence to PrEP were key determinants to its effectiveness.

In a release, the study authors state that “the cost-effectiveness of pre-exposure prophylaxis is likely to depend on considerations such as cost, the epidemic context, pre-exposure prophylaxis programme coverage and prioritisation strategies, as well as individual adherence levels and pre-exposure prophylaxis efficacy estimates.”

To read the study, click here.

To read the release, click here.

Search: Pre-exposure prophylaxis, PrEP, antiretrovirals, ARV, MSM, men who have sex with men, injection drug users, PLOS Medicine, cost-effective.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    Hillcrester
    Ramona
    California


    juliar33
    brooklyn
    New York


    latinpozdallas
    Dallas
    Texas


    thebake
    Sioux Falls
    South Dakota
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Is HIV/AIDS adequately portrayed in pop culture?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.